logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Manufacturers
    3. Novo Nordisk

    Novo Nordisk drugs

    FiltersReset Filters
    19 results

    • alhemo

      (concizumab)
      Novo Nordisk
      Usage: Alhemo is indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 12 and older with hemophilia A (factor VIII deficiency with inhibitors) and hemophilia B (factor IX deficiency with inhibitors).

    • fiasp

      (insulin aspart injection)
      Novo Nordisk
      Usage: FIASP is indicated for improving glycemic control in both adult and pediatric patients with diabetes mellitus.

    • levemir

      (insulin detemir)
      Novo Nordisk
      Usage: LEVEMIR is indicated for improving glycemic control in adults and pediatric patients with diabetes mellitus. However, it is not recommended for treating diabetic ketoacidosis.

    • macrilen

      (Macimorelin acetate)
      Novo Nordisk
      Usage: MACRILEN is used for diagnosing adult growth hormone deficiency (AGHD). Its safety and diagnostic effectiveness in individuals with a body mass index (BMI) greater than 40 kg/m² have not been established.

    • norditropin

      (somatropin)
      Novo Nordisk
      Usage: NORDITROPIN is indicated for pediatric patients with growth failure from inadequate growth hormone secretion, short stature due to Noonan or Turner syndrome, short stature born SGA, Idiopathic Short Stature, and Prader-Willi syndrome. For adults, it is used to replace endogenous growth hormone in those with deficiency.

    • novolog - insulin aspart injection, solution

      (Water Injection)
      Novo Nordisk

    • novolog mix 70/30- insulin aspart injection, suspension

      (Insulin Aspart)
      Novo Nordisk

    • ozempic

      (semaglutide)
      Novo Nordisk
      Usage: OZEMPIC is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes. It also reduces the risk of major adverse cardiovascular events and helps in preventing kidney disease progression in patients with type 2 diabetes and chronic kidney disease.

    • rebinyn - coagulation factor ix recombinant, glycopegylated

      (Coagulation Factor Ix Recombinant, Glycopegylated)
      Novo Nordisk

    • rivfloza

      (nedosiran)
      Novo Nordisk
      Usage: RIVFLOZA is indicated for lowering urinary oxalate levels in children aged 2 years and older and adults with primary hyperoxaluria type 1 (PH1) who have relatively preserved kidney function (eGFR ≥30 mL/min/1.73 m²).